O39.SI · SES · Financial Services
Oversea-Chinese Banking Corporation Limited
Also onConsensus Drift
Implied value per share
SGD 45.71
Market price
SGD 31.38
Implied upside
+45.7%
5-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case
Value Per Share
Same forecast, different terminal treatment. Percentages vs price.
Forecast Cashflows
Reporting currency (SGD). Outflows negative.
| Line | FY26 | FY27 | FY28 | FY29 | FY30 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | SGD 15.9bn | SGD 17.3bn | SGD 18.9bn | SGD 20.6bn | SGD 22.5bn | +9.1% |
| EBIT | SGD 9.8bn | SGD 10.7bn | SGD 11.7bn | SGD 12.7bn | SGD 13.9bn | +9.1% |
| NOPAT | SGD 8.3bn | SGD 9.1bn | SGD 9.9bn | SGD 10.8bn | SGD 11.8bn | +9.1% |
| Add depreciation & amortisation | SGD 650.5m | SGD 709.8m | SGD 774.5m | SGD 845.1m | SGD 922.1m | +9.1% |
| Less capital expenditure | SGD -764.9m | SGD -834.7m | SGD -910.7m | SGD -993.7m | SGD -1.1bn | +9.1% |
| Less increase in working capital | SGD 1.1bn | SGD 1.2bn | SGD 1.3bn | SGD 1.4bn | SGD 1.5bn | -9.1% |
| Free cashflow to firm | SGD 9.3bn | SGD 10.1bn | SGD 11.1bn | SGD 12.1bn | SGD 13.2bn | +9.1% |
| Discount factor | 0.9672 | 0.9047 | 0.8463 | 0.7917 | 0.7405 | - |
| Present value | SGD 9.0bn | SGD 9.2bn | SGD 9.4bn | SGD 9.6bn | SGD 9.8bn | +2.1% |
| Present Value Of The Forecast | SGD 46.8bn | |||||
Discount Rate
Source shown per component. All overridable above.
| Risk-free rate | 4.20% | USD assumption - no free live source available for this market (assumption) |
| Equity risk premium | 6.50% | Market assumption |
| Beta | 0.471 | Reported 0.210, pulled toward 1.0 (Blume) |
| Cost of equity | 7.26% | Risk-free + beta x equity risk premium |
| Cost of debt | 6.20% | Implied cost of debt of 35.0% is not a credible funding cost, so risk-free + 2bp is assumed instead. Interest expense and reported debt are measuring different things - common for banks, whose interest expense includes deposits that total debt excludes. |
| Market capitalisation | SGD 141.1bn | 82.1% of capital |
| Total debt | SGD 30.7bn | 17.9% of capital, book value as a proxy |
| Tax rate | 15.1% | Effective, capped at statutory |
| WACC | 6.90% | E/V x Re + D/V x Rd x (1 - t) |
Terminal Value
Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.
Perpetuity growth at 2.50%
75% of EV
- Forecast FCFF, final year
- SGD 13.2bn
- Capex at depreciation, working capital in reinvestment
- SGD 11.9bn
- Less reinvestment at g/ROIC (29.9% of NOPAT)
- SGD -3.6bn
- Capitalised
- SGD 8.3bn
- ROIC (reported)
- 8.4%
- Terminal value, undiscounted
- SGD 194.2bn
- Terminal value, discounted
- SGD 143.8bn
- Enterprise value
- SGD 190.6bn
- Less net debt
- SGD -15.0bn
- Equity value
- SGD 205.6bn
Exit at 13.0x EBITDA
75% of EV
- Terminal value, undiscounted
- SGD 192.6bn
- Terminal value, discounted
- SGD 142.6bn
- Enterprise value
- SGD 189.4bn
- Less net debt
- SGD -15.0bn
- Equity value
- SGD 204.4bn
Spread between methods: 1%.
Sensitivity
Value per share (SGD) by discount rate and long-run growth.
| Long-run growth | |||||
|---|---|---|---|---|---|
| Discount rate | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
| 4.90% | 66.46 | 71.27 | 78.04 | 88.29 | 105.75 |
| 5.90% | 52.65 | 54.63 | 57.15 | 60.49 | 65.18 |
| 6.90% | 43.94 | 44.75 | 45.71 | 46.89 | 48.39 |
| 7.90% | 37.94 | 38.19 | 38.48 | 38.80 | 39.17 |
| 8.90% | 33.81 | 33.91 | 34.01 | 34.11 | 34.22 |
Outlined: this model. Green text: above today's price of 31.38. Shading: distance from this model's own value.
Priced In
What each input would have to be to justify the current price, one at a time.
| Input | Model | Implied | Gap |
|---|---|---|---|
| Revenue growth, every year | 9.1% | 0.2% | -8.9pp |
| EBIT margin | 61.8% | 40.2% | -21.6pp |
| Discount rate | 6.9% | 9.7% | +2.8pp |
Live formulas, not pasted numbers - edit a driver and the workbook reprices.
Yahoo Finance and RBA data. General information, not advice. Methodology.